Pipeline
The pipeline is built on two platforms: SCI-110 (THC + CannAmide™) and SCI-210 (CBD + CannAmide™).
SCI-110
Tourette Syndrome
Flagship clinical asset. Unique and proprietary cannabinoid-based formulation (THC + PEA) designed to reduce tic severity. Phase IIb is underway.
For more info >>Alzheimer’s Disease & Agitation
Phase IIa completed, with positive final results meeting primary and secondary endpoints.
For more info >>CannAmide™ — Pain and Inflammation
CannAmide™ is described for pain and inflammation. The presentation states that chronic pain is estimated to affect more than 40% of people worldwide, that several existing pain medications are associated with substantial side effects with chronic use, and that PEA has been shown to reduce chronic pain while maintaining safety and tolerability.
SCI-210
Autism Spectrum Disorder
SCI-210 for ASD is presented as Phase III* via the medical cannabis route. Randomized, double-blind, placebo-controlled crossover study in children.
For more info >>Status Epilepticus
The Company intends to use the SCI-210 platform (PEA + CBD) to seek maximum effect with minimal adverse side effects. Positive study results were announced in December 2022 from work conducted at The Chaim Sheba Medical Center in Israel.